We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb content piece image
Credit: rawpixel
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Ubiquigent Limited has announced the continuation of a collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalize on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.

The central role of ubiquitylation in diverse cellular processes, including protein degradation, makes the enzymes responsible for ubiquitylation and de-ubiquitylation very attractive drug targets to address a range of human pathologies. Since the clinical approval of proteasome inhibitors, there has been growing interest in modulating the various components of the ubiquitylation machinery, such as DUBs, or exploiting the ubiquitin pathway via PROTACs and molecular glues to target the undruggable genome.

Ubiquigent’s Managing Director, Mr. Jason Mundin commented: “We are delighted to continue this partnership and look forward to supporting Bristol Myers Squibb in the development of novel DUB inhibitors for patients with unmet medical needs.”